Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 3, 2010, Pages 275-281

  Bloss, Emily ^a   Kuksa L ^b   Holtz, T H ^a   Riekstina, V ^b   Skripconoka V ^b   Kammerer, S ^a   Leimane, V ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b State Agency of Tuberculosis and Lung Diseases   (Latvia)

Author keywords

Adverse events; Latvia; Multidrug resistance; Tuberculosis

Indexed keywords

AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; KANAMYCIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CONVULSION; DERMATITIS; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; FEMALE; HEARING LOSS; HEPATITIS; HUMAN; HYPERURICEMIA; HYPOTHYROIDISM; JAUNDICE; KIDNEY FAILURE; LATVIA; LUNG CAVITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL DISEASE; MULTIDRUG RESISTANT TUBERCULOSIS; NAUSEA; NEUROPATHY; PRIORITY JOURNAL; PRURITUS; RETROSPECTIVE STUDY; SYMPTOM; TINNITUS; UNSPECIFIED SIDE EFFECT; VESTIBULAR DISORDER; VISUAL IMPAIRMENT; VOMITING;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LATVIA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 77949501765     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Francis J Curry National Tuberculosis Center and California Department of Health Services. Chapter 1: epidemiology and background. In: Drug-resistant tuberculosis: a survival guide for clinicians. 2nd ed. Richmond, CA, USA: California Department of Public Health, 2008: pp 1-16.
2. World Health Organization. Anti-tuberculosis drug resistance in the world. Report no. 4. Global project on anti-tuberculosis drug resistance in the world: prevalence and trends. WHO/HTM/TB/2008.394. Geneva, Switzerland: WHO, 2008. http://whqlibdoc.who.int/hq/2008/WHO-HTM-TB-2008.394-eng.pdf Accessed November 2009.
3. American Thoracic Society, Centers for Disease Control and Prevention (CDC), Infectious Diseases Society. Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
4. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. WHO/CDS/TB/2003.313. Geneva, Switzerland: WHO, 2003. http://whqlibdoc.who.int/HQ/2003/WHO-CDS-TB-2003.313-eng.pdf Accessed November 2009.
5. Rieder H L, Chonde T M, Myking H, et al. The Public Health Service National Tuberculosis Reference Laboratory and the national laboratory network. Minimum requirements, role and operation in a low-income country. Paris, France: Inter national Union Against Tuberculosis and Lung Disease, 1998.
6. Canetti G, Froman S, Grosset J, et al. Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull World Health Organ 1963; 29: 565-578.
7. Leimane V, Riekstina V, Holtz T H, Zarovska E, Skripconoka V. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365: 318-326.
8. Laserson K F, Thorpe L E, Leimane V, et al. Speaking the same language: treatment outcome defi nitions for multidrug resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 640-645.
9. Bailey K V, Ferro-Luzzi A. Use of body mass index of adults in assessing individual and community health status. Bull World Health Organ 1995; 73: 673-680.
10. Shin S S, Pasechnikov A D, Gelmanova I Y, et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis 2007; 11: 1314-1320.
11. Güngör G, Ozmen I, Bölükbaşi Y, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 1373-1377.
12. Ghosh C S, Thomas J, Prabhu D, et al. Adverse events during therapy for multidrug resistant tuberculosis in a tertiary care setting. Pulmon 2007; 9: 23-28.
13. Goble M, Iseman M D, Madsen L A, Waite D, Ackerson L, Horsburgh C R. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527-532.
14. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2006.361. Geneva, Switzerland: WHO, 2006. http://whqlibdoc.who.int/publications/2006/9241546956-eng.pdf Accessed November 2009.
15. Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 2004; 8: 1382-1384.
16. Vega P, Sweetland A, Acha J, et al. Psychiatric issues in the management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2004; 8: 749-759.
17. Furin J J, Mitnick C D, Shin S S, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001; 5: 648-655.
18. Francis J Curry National Tuberculosis Center and California Department of Health Services. Chapter 4: medication fact sheets. In: Drug-resistant tuberculosis: a survival guide for clinicians. 2nd ed. Richmond, CA, USA: California Department of Public Health, 2008: pp 58-92.
19. Helmy B. Side effects of cycloserine. Scand Respir Dis 1970; 71 (Suppl): S220-S225.
20. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008. http://whqlibdoc.who.int/publications/2008/ 9789241547581-eng.pdf Accessed November 2009.